Forefront Analytics, LLC Verona Pharma PLC Transaction History

Forefront Analytics, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.14 - $13.59 $56,924 - $186,862	-13,750 Reduced 50.56%	13,446 $138,000
Q2 2022 Aug 10, 2022	SELL	$3.55 - $5.06 $30,033 - $42,807	-8,460 Reduced 23.73%	27,196 $112,000
Q1 2022 May 09, 2022	BUY	$4.82 - $6.98 $7,471 - $10,819	1,550 Added 4.54%	35,656 $179,000
Q4 2021 Feb 11, 2022	BUY	$3.91 - $7.08 $3,714 - $6,726	950 Added 2.87%	34,106 $229,000
Q3 2021 Nov 15, 2021	BUY	$5.29 - $6.35 $93,368 - $112,077	17,650 Added 113.83%	33,156 $181,000
Q2 2021 Aug 10, 2021	BUY	$5.72 - $9.09 $8,030 - $12,762	1,404 Added 9.96%	15,506 $104,000
Q1 2021 May 13, 2021	BUY	$7.08 - $9.33 $99,842 - $131,571	14,102 New	14,102 $118,000

167

68.7M

704K

685K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Forefront Analytics, LLC, based on Form 13F filings with the SEC.

Stay updated on Forefront Analytics, LLC with notifications on news.